Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Vasopressin Treatment in Children With Autism
NCT03204786Phase 3Completed
- Sponsor
- Stanford University
- Start
- Feb 2018
- Primary completion
- Mar 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of vasopressin in Autism Spectrum Disorder (ASD), sponsored by Stanford University. Started Feb 2018; status: completed.
02
Drugs
vasopressin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03204786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03204786.